Vision, Integrity, Expertise

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.

Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous T-cell lymphoma, oral mucositis, pediatric Crohn’s disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, gastrointestinal acute radiation syndrome, and melioidosis.

Dr. Christopher Schaber, President & CEO of Soligenix Inc. talks about the company’s activities.

Video provided courtesy of Thomson Reuters Insider Network

 
* * Latest News Latest News
 
* * Relevant Publications Publications
 
* * Presentations Presentations

Corporate Presentation
August 15, 2016
View the presentation (pdf)


Dusquetide (SGX94) TechWatch Presentation
August 2016

View the presentation on YouTube

View the presentation (pdf)


SGX942 MASCC Presentation
June 25, 2016

View the presentation on YouTube

View the presentation (pdf)

Our Clinical Trials

Learn more >

Partnering with Us

Learn more >